Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Herrmann

Showing results (181-190 of 721) with videos related to

Pageof 73
Sort By:
Oncology Research and Treatment|November 24, 2021
The Future Role of PET Imaging in Metastatic Breast CancerKim M Pabst, Thomas Decker, David Kersting, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|May 1, 2020
Radiomics Analysis of Multiparametric PET/MRI for N- and M-Staging in Patients with Primary Cervical CancerLale Umutlu, Felix Nensa, Aydin Demircioglu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 13, 2023
Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?Benedikt Feuerecker, Clemens Kratochwil, Hojjat Ahmadzadehfar, et al.
European Urology Oncology|April 25, 2019
Theranostics for Advanced Prostate Cancer: Current Indications and Future DevelopmentsAndrea Farolfi, Wolfgang Fendler, Amir Iravani, et al.
Data in Brief|March 5, 2021
Insights into immunometabolism: A dataset correlating the <sup>18</sup>FDG PET/CT maximum standard uptake value of the primary tumor with the CCL18 serum level in non-small cell lung cancerTugba Dönmez, Kerstin Höhne, Gernot Zissel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 6, 2017
<sup>18</sup>F-FDG PET/MRI in patients suffering from lymphoma: how much MRI information is really needed?Julian Kirchner, Cornelius Deuschl, Johannes Grueneisen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 19, 2019
In Vitro and In Vivo Characterization of an <sup>18</sup>F-AlF-Labeled PSMA Ligand for Imaging of PSMA-Expressing XenograftsSusanne Lütje, Gerben M Franssen, Ken Herrmann, et al.
Clinical Nuclear Medicine|December 30, 2014
Paralytic subileus as an adverse effect of amino acid-based nephroprotection in a patient undergoing peptide receptor radionuclide therapyRudolf A Werner, Joachim Brumberg, Alexander Dierks, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 24, 2017
Imaging children suffering from lymphoma: an evaluation of different <sup>18</sup>F-FDG PET/MRI protocols compared to whole-body DW-MRIJulian Kirchner, Cornelius Deuschl, Bernd Schweiger, et al.
Asian Cardiovascular & Thoracic Annals|July 13, 2023
Accuracy of nodal staging by 18F-FDG-PET/CT in limited disease small-cell lung cancerJan Hockmann, Hubertus Hautzel, Kaid Darwiche, et al.
Pageof 73

Showing results (181-190 of 721) with videos related to

Sort By:
Pageof 73
Oncology Research and Treatment|November 24, 2021
The Future Role of PET Imaging in Metastatic Breast CancerKim M Pabst, Thomas Decker, David Kersting, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|May 1, 2020
Radiomics Analysis of Multiparametric PET/MRI for N- and M-Staging in Patients with Primary Cervical CancerLale Umutlu, Felix Nensa, Aydin Demircioglu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 13, 2023
Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?Benedikt Feuerecker, Clemens Kratochwil, Hojjat Ahmadzadehfar, et al.
European Urology Oncology|April 25, 2019
Theranostics for Advanced Prostate Cancer: Current Indications and Future DevelopmentsAndrea Farolfi, Wolfgang Fendler, Amir Iravani, et al.
Data in Brief|March 5, 2021
Insights into immunometabolism: A dataset correlating the <sup>18</sup>FDG PET/CT maximum standard uptake value of the primary tumor with the CCL18 serum level in non-small cell lung cancerTugba Dönmez, Kerstin Höhne, Gernot Zissel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 6, 2017
<sup>18</sup>F-FDG PET/MRI in patients suffering from lymphoma: how much MRI information is really needed?Julian Kirchner, Cornelius Deuschl, Johannes Grueneisen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 19, 2019
In Vitro and In Vivo Characterization of an <sup>18</sup>F-AlF-Labeled PSMA Ligand for Imaging of PSMA-Expressing XenograftsSusanne Lütje, Gerben M Franssen, Ken Herrmann, et al.
Clinical Nuclear Medicine|December 30, 2014
Paralytic subileus as an adverse effect of amino acid-based nephroprotection in a patient undergoing peptide receptor radionuclide therapyRudolf A Werner, Joachim Brumberg, Alexander Dierks, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 24, 2017
Imaging children suffering from lymphoma: an evaluation of different <sup>18</sup>F-FDG PET/MRI protocols compared to whole-body DW-MRIJulian Kirchner, Cornelius Deuschl, Bernd Schweiger, et al.
Asian Cardiovascular & Thoracic Annals|July 13, 2023
Accuracy of nodal staging by 18F-FDG-PET/CT in limited disease small-cell lung cancerJan Hockmann, Hubertus Hautzel, Kaid Darwiche, et al.
Pageof 73